Genprex | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -5.

EBIT: As of FY2025 Q3, the actual value is USD -2.893 M.

Segment Revenue

• Genprex, Inc. did not report any revenue for the three and nine months ended September 30, 2025, and 2024.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the net loss was $3,799,240, compared to $4,315,987 for the same period in 2024, representing a decrease of $516,747 or 12%.
• For the nine months ended September 30, 2025, the net loss was $12,438,742, compared to $16,780,702 for the same period in 2024, representing a decrease of $4,341,960 or 26%.
• Research and Development Expense: For the three months ended September 30, 2025, R&D expenses were $2,192,881, compared to $2,756,081 for the same period in 2024, a decrease of $563,200 or 20%.
• For the nine months ended September 30, 2025, R&D expenses were $7,232,370, compared to $7,696,983 for the same period in 2024, a decrease of $464,613 or 6%.
• General and Administrative Expense: For the three months ended September 30, 2025, G&A expenses were $1,153,032, compared to $1,566,085 for the same period in 2024, a decrease of $413,053 or 26%.
• For the nine months ended September 30, 2025, G&A expenses were $4,764,617, compared to $9,135,225 for the same period in 2024, a decrease of $4,370,608 or 48%.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $11,212,938, compared to $14,053,136 for the same period in 2024, a decrease of $2,840,198 or 20%.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $10,714,593, compared to $8,029,143 for the same period in 2024, an increase of $2,685,450.

Unique Metrics

• Derivative Liability: The fair value of the ELOC derivative liability was $243,000 as of September 30, 2025.

Future Outlook and Strategy

• Core Business Focus: Genprex plans to continue enrolling patients in its Acclaim-1 and Acclaim-3 clinical trials, with interim enrollment expected to be completed in the first half of 2026.
• Non-Core Business: The company is working on diabetes gene therapy, with plans to submit a request to the FDA for IND-enabling studies by the end of 2025.
• Priority: Genprex aims to raise additional capital to fund its operations and clinical trials, with current cash expected to fund operations into March 2026.